Economic evaluations of gastroesophageal reflux disease medical management

Andrew J. Gawron, Dustin D. French, John E. Pandolfino, Colin Howden

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Background: Gastroesophageal reflux disease (GERD) contributes to substantial medication use and costs worldwide. Economic evaluations provide insight into the value of healthcare, taking into account cost, quality, and benefits of particular treatments. Objectives: Our objectives were to systematically review the existing literature to identify economic evaluations of GERD management strategies, to assess the scientific quality of these reports, and to summarize the economic outcomes of these evaluations. Methods: We identified economic evaluations and cost studies of GERD management strategies by searching PubMed and the UK NHS Economic Evaluation Database via the Cochrane Library. Searching was restricted to articles in English-language journals from July 2003 to July 2013. Cost-identification articles were excluded from the final analysis. Results: Eighteen articles were included in the final analysis; 61 % of these met all criteria for quality reporting. Overall, proton pump inhibitor (PPI) therapy was preferred (most effective and least costly) as empiric therapy for patients with reflux symptoms, except in patient populations with high Helicobacter pylori prevalence (>40 %). Initial empiric PPI therapy (vs. initial endoscopy stratification or H. pylori testing) is likely the most cost-effective initial strategy for patients with typical GERD symptoms. Surgery may be cost effective in patients with chronic GERD symptoms at time horizons of 3-10 years. Endoscopic anti-reflux procedures were not cost effective based on available data. Conclusions: Further economic evaluations should adhere to standard reporting measures of cost estimates and outcomes, and should attempt to account for and compare the large heterogeneity of patient phenotypes and treatment effects seen with anti-reflux therapies.

Original languageEnglish (US)
Pages (from-to)745-758
Number of pages14
JournalPharmacoEconomics
Volume32
Issue number8
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Disease Management
Gastroesophageal Reflux
Cost-Benefit Analysis
Costs and Cost Analysis
Proton Pump Inhibitors
Helicobacter pylori
Therapeutics
PubMed
Endoscopy
Libraries
Language
Outcome Assessment (Health Care)
Databases
Delivery of Health Care
Phenotype
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Economic evaluations of gastroesophageal reflux disease medical management. / Gawron, Andrew J.; French, Dustin D.; Pandolfino, John E.; Howden, Colin.

In: PharmacoEconomics, Vol. 32, No. 8, 01.01.2014, p. 745-758.

Research output: Contribution to journalReview article

Gawron, Andrew J. ; French, Dustin D. ; Pandolfino, John E. ; Howden, Colin. / Economic evaluations of gastroesophageal reflux disease medical management. In: PharmacoEconomics. 2014 ; Vol. 32, No. 8. pp. 745-758.
@article{57f314232e294d8cb9ddd667b05d51dc,
title = "Economic evaluations of gastroesophageal reflux disease medical management",
abstract = "Background: Gastroesophageal reflux disease (GERD) contributes to substantial medication use and costs worldwide. Economic evaluations provide insight into the value of healthcare, taking into account cost, quality, and benefits of particular treatments. Objectives: Our objectives were to systematically review the existing literature to identify economic evaluations of GERD management strategies, to assess the scientific quality of these reports, and to summarize the economic outcomes of these evaluations. Methods: We identified economic evaluations and cost studies of GERD management strategies by searching PubMed and the UK NHS Economic Evaluation Database via the Cochrane Library. Searching was restricted to articles in English-language journals from July 2003 to July 2013. Cost-identification articles were excluded from the final analysis. Results: Eighteen articles were included in the final analysis; 61 {\%} of these met all criteria for quality reporting. Overall, proton pump inhibitor (PPI) therapy was preferred (most effective and least costly) as empiric therapy for patients with reflux symptoms, except in patient populations with high Helicobacter pylori prevalence (>40 {\%}). Initial empiric PPI therapy (vs. initial endoscopy stratification or H. pylori testing) is likely the most cost-effective initial strategy for patients with typical GERD symptoms. Surgery may be cost effective in patients with chronic GERD symptoms at time horizons of 3-10 years. Endoscopic anti-reflux procedures were not cost effective based on available data. Conclusions: Further economic evaluations should adhere to standard reporting measures of cost estimates and outcomes, and should attempt to account for and compare the large heterogeneity of patient phenotypes and treatment effects seen with anti-reflux therapies.",
author = "Gawron, {Andrew J.} and French, {Dustin D.} and Pandolfino, {John E.} and Colin Howden",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s40273-014-0164-8",
language = "English (US)",
volume = "32",
pages = "745--758",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "8",

}

TY - JOUR

T1 - Economic evaluations of gastroesophageal reflux disease medical management

AU - Gawron, Andrew J.

AU - French, Dustin D.

AU - Pandolfino, John E.

AU - Howden, Colin

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Gastroesophageal reflux disease (GERD) contributes to substantial medication use and costs worldwide. Economic evaluations provide insight into the value of healthcare, taking into account cost, quality, and benefits of particular treatments. Objectives: Our objectives were to systematically review the existing literature to identify economic evaluations of GERD management strategies, to assess the scientific quality of these reports, and to summarize the economic outcomes of these evaluations. Methods: We identified economic evaluations and cost studies of GERD management strategies by searching PubMed and the UK NHS Economic Evaluation Database via the Cochrane Library. Searching was restricted to articles in English-language journals from July 2003 to July 2013. Cost-identification articles were excluded from the final analysis. Results: Eighteen articles were included in the final analysis; 61 % of these met all criteria for quality reporting. Overall, proton pump inhibitor (PPI) therapy was preferred (most effective and least costly) as empiric therapy for patients with reflux symptoms, except in patient populations with high Helicobacter pylori prevalence (>40 %). Initial empiric PPI therapy (vs. initial endoscopy stratification or H. pylori testing) is likely the most cost-effective initial strategy for patients with typical GERD symptoms. Surgery may be cost effective in patients with chronic GERD symptoms at time horizons of 3-10 years. Endoscopic anti-reflux procedures were not cost effective based on available data. Conclusions: Further economic evaluations should adhere to standard reporting measures of cost estimates and outcomes, and should attempt to account for and compare the large heterogeneity of patient phenotypes and treatment effects seen with anti-reflux therapies.

AB - Background: Gastroesophageal reflux disease (GERD) contributes to substantial medication use and costs worldwide. Economic evaluations provide insight into the value of healthcare, taking into account cost, quality, and benefits of particular treatments. Objectives: Our objectives were to systematically review the existing literature to identify economic evaluations of GERD management strategies, to assess the scientific quality of these reports, and to summarize the economic outcomes of these evaluations. Methods: We identified economic evaluations and cost studies of GERD management strategies by searching PubMed and the UK NHS Economic Evaluation Database via the Cochrane Library. Searching was restricted to articles in English-language journals from July 2003 to July 2013. Cost-identification articles were excluded from the final analysis. Results: Eighteen articles were included in the final analysis; 61 % of these met all criteria for quality reporting. Overall, proton pump inhibitor (PPI) therapy was preferred (most effective and least costly) as empiric therapy for patients with reflux symptoms, except in patient populations with high Helicobacter pylori prevalence (>40 %). Initial empiric PPI therapy (vs. initial endoscopy stratification or H. pylori testing) is likely the most cost-effective initial strategy for patients with typical GERD symptoms. Surgery may be cost effective in patients with chronic GERD symptoms at time horizons of 3-10 years. Endoscopic anti-reflux procedures were not cost effective based on available data. Conclusions: Further economic evaluations should adhere to standard reporting measures of cost estimates and outcomes, and should attempt to account for and compare the large heterogeneity of patient phenotypes and treatment effects seen with anti-reflux therapies.

UR - http://www.scopus.com/inward/record.url?scp=84906934382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906934382&partnerID=8YFLogxK

U2 - 10.1007/s40273-014-0164-8

DO - 10.1007/s40273-014-0164-8

M3 - Review article

VL - 32

SP - 745

EP - 758

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 8

ER -